36
Participants
Start Date
July 31, 2009
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Counseling
"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~1. One week prior to the target quit date (TQD)~2. Two weeks post-TQD~3. Four weeks post-TQD"
Self-help guide
A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
Pharmacotherapy
"8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion"
Genetic feedback, verbal
During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
Genetic feedback, printed
After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
SRI International, Menlo Park
Stanford University School of Medicine, Stanford
Group Health Research Institute, Seattle
Collaborators (1)
SRI International
INDUSTRY
Johns Hopkins University
OTHER
University of Bristol
OTHER
National Institute on Drug Abuse (NIDA)
NIH
Stanford University
OTHER